Clal Biotechnology Industries Ltd. 13D and 13G filings for Elicio Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-04-10 4:01 pm Sale |
2024-04-08 | 13D | Elicio Therapeutics, Inc. ELTX |
Clal Biotechnology Industries Ltd. | 481,727 4.680% |
-117,470 (-19.60%) |
Filing |
| 2024-03-20 9:07 pm Sale |
2024-03-18 | 13D | Elicio Therapeutics, Inc. ELTX |
Clal Biotechnology Industries Ltd. | 599,197 5.830% |
-90,372 (-13.11%) |
Filing |
| 2023-12-27 4:07 pm Unchanged |
2023-12-22 | 13D | Elicio Therapeutics, Inc. ELTX |
Clal Biotechnology Industries Ltd. | 689,569 7.120% |
0 (Unchanged) |
Filing |
| 2023-08-30 5:16 pm Unchanged |
2023-08-28 | 13D | Elicio Therapeutics, Inc. ELTX |
Clal Biotechnology Industries Ltd. | 689,569 8.160% |
0 (Unchanged) |
Filing |
| 2023-06-12 4:01 pm Purchase |
2023-06-09 | 13D | Elicio Therapeutics, Inc. ELTX |
Clal Biotechnology Industries Ltd. | 689,569 7.110% |
689,569 (New Position) |
Filing |